Navigation Links
Keryx Biopharmaceuticals Announces Live Webcast of Upcoming Analyst Day
Date:6/19/2012

NEW YORK, June 19, 2012 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that its upcoming Analyst Day will be webcast live on Thursday, June 21, 2012 at 4:30 pm ET. Scheduled speakers include:

Julia Lewis, M.D., will provide her perspective on the Zerenex (ferric citrate) Phase 3 clinical program and the potential Zerenex product profile.
-- Professor of Medicine, Division of Nephrology, Vanderbilt University School of Medicine.

Geoffrey Block, M.D., will discuss the potential for Zerenex in pre-dialysis.
-- Director of Research, Denver Nephrology and Associate Clinical Professor in Medicine, University of Colorado Health Sciences Center.

David Goldfarb, M.D., will discuss the potential importance of citrate.
-- Chief, Nephrology Division, NY Campus of NY Harbor Health Care Veterans Affairs System and Professor of Medicine & Physiology, NYU School of Medicine.

To access the live audio webcast, please visit the Company's Investor Relations section of their website (http://investors.keryx.com). An archived version of the webcast will become available following the conclusion of the live presentation.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is headquartered in New York City.  

KERYX CONTACT:

Lauren Fischer

Director - Investor Relations

Keryx Biopharmaceuticals, Inc.

Tel: 212.531.5965

E-mail: lfischer@keryx.com


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
3. Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B
4. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
5. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
6. OncoSec Announces Issuance of New Patent for Method of Use
7. ATCC Announces Agreement with Life Technologies Corporation to Sell and Distribute Green Fluorescent Protein (GFP)-based Materials
8. Trovagene, Inc. Announces Full Exercise of Over-Allotment Option by Aegis Capital Corp.
9. NanoLogix Announces Development of Multi-Well, Rapid Diagnostic Test Variant and Exhibits at the American Society for Microbiology General Meeting in San Francisco
10. UK supplier of graphenes announces exclusive sales agency agreement with leading USA distributor
11. Generex Announces Scheduling of USFDA End-of-Phase II Meeting for the AE37 Breast Cancer Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... CA (PRWEB) , ... May 05, 2016 , ... ... closed on a definitive agreement to acquire Algynomics, a research-stage pain diagnostics company. ... data to identify individuals at increased risk for the development of chronic pain, ...
(Date:5/5/2016)... ... 2016 , ... American Process, Inc. (API) announced that the ... 9,322,133 and 9,322,134, to API and its affiliated companies for BioPlus® nanocellulose technology. ... compositions. In addition to these patents and U.S. Patent No. 9,187,865 awarded ...
(Date:5/5/2016)... 2016  Why are two uber-successful former agency presidents ... launching a new venture—yet going about things in ... truly helping clients raise the value of their offerings ... different type of collaboration. The result is ... and medical device sectors. Elevate specializes in shaping and ...
(Date:5/5/2016)... ... May 05, 2016 , ... ProMIS Neurosciences ... its first three targets, it has identified a fourth in a series of ... the development and progression of Alzheimer’s disease (AD). , “This discovery ...
Breaking Biology Technology:
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
(Date:4/28/2016)... India , April 28, 2016 ... Infosys (NYSE: INFY ), and Samsung SDS, a ... that will provide end customers with a more secure, ... services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... services, but it also plays a fundamental part in enabling ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
Breaking Biology News(10 mins):